CURRENTOPINION The year in cardiology: heart failure 2014

year 2014 has become a remarkable year for heart failure. A bad start was caused by the publication of TOPCAT, showing that spir-onolactone did not prove to be beneficial for the treatment of patients with heart failure and preserved ejection fraction (HFpEF). Nevertheless, further insights in the study yields a few bright spots, and treatment with spironolactone might still be considered in patients with HFpEF. In acute heart failure, additional data were pub-lishedon the effects of serelaxin. Serelaxin reducedwedgepressures, had similar effects in acute heart failure patients with and without a reduced ejection fraction, and had a neutral effect on diuretic re-sponse. But the most important news was related to the results of PARADIGM, where LCZ696, the first-in-class angiotensin-receptor neprilysin inhibitor, proved to be superior to enalapril in reducing mortality and morbidity in patients with heart failure and reduced ejection fraction (HFrEF)